Literature DB >> 23885148

Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation.

Piotr M Wierzbicki1, Krystian Adrych, Dorota Kartanowicz, Marcin Stanislawowski, Anna Kowalczyk, Janusz Godlewski, Iwona Skwierz-Bogdanska, Krzysztof Celinski, Tomasz Gach, Jan Kulig, Bartlomiej Korybalski, Zbigniew Kmiec.   

Abstract

AIM: To investigate large tumor suppressor 1 (LATS1) expression, promoter hypermethylation, and microsatellite instability in colorectal cancer (CRC).
METHODS: RNA was isolated from tumor tissue of 142 CRC patients and 40 colon mucosal biopsies of healthy controls. After reverse transcription, quantitative polymerase chain reaction (PCR) was performed, and LATS1 expression was normalized to expression of the ACTB and RPL32 housekeeping genes. To analyze hypermethylation, genomic DNA was isolated from 44 tumor CRC biopsies, and methylation-specific PCR was performed. Microsatellite instability (MSI) status was checked with PCR using BAT26, BAT25, and BAT40 markers in the genomic DNA of 84 CRC patients, followed by denaturing gel electrophoresis.
RESULTS: Decreased LATS1 expression was found in 127/142 (89.4%) CRC cases with the average ratio of the LATS1 level 10.33 ± 32.64 in CRC patients vs 32.85 ± 33.56 in healthy controls. The lowest expression was found in Dukes' B stage tumors and G1 (well-differentiated) cells. Hypermethylation of the LATS1 promoter was present in 25/44 (57%) CRC cases analyzed. LATS1 promoter hypermethylation was strongly associated with decreased gene expression; methylated cases showed 162× lower expression of LATS1 than unmethylated cases. Although high-grade MSI (mutation in all three markers) was found in 14/84 (17%) cases and low-grade MSI (mutation in 1-2 markers) was found in 30/84 (36%) cases, we found no association with LATS1 expression.
CONCLUSION: Decreased expression of LATS1 in CRC was associated with promoter hypermethylation, but not MSI status. Such reduced expression may promote progression of CRC.

Entities:  

Keywords:  Colorectal cancer; Large tumor suppressor 1; Microsatellite instability; Promoter hypermethylation; Quantitative polymerase chain reaction; Reduced expression; Salvador-Warts-Hippo pathway

Mesh:

Substances:

Year:  2013        PMID: 23885148      PMCID: PMC3718905          DOI: 10.3748/wjg.v19.i27.4363

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  52 in total

1.  Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis.

Authors:  X Yang; D M Li; W Chen; T Xu
Journal:  Oncogene       Date:  2001-10-04       Impact factor: 9.867

2.  KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Authors:  S Moleirinho; N Chang; A H Sims; A M Tilston-Lünel; L Angus; A Steele; V Boswell; S C Barnett; C Ormandy; D Faratian; F J Gunn-Moore; P A Reynolds
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Loss of heterozygosity on chromosome 1 and 9 and hormone receptor analysis of metastatic malignant melanoma presenting in breast.

Authors:  Michael W Beaty; Martha Quezado; Mark E Sobel; Paul Duray; Maria J Merino
Journal:  Int J Surg Pathol       Date:  2005-01       Impact factor: 1.271

Review 5.  Loss of heterozygosity analysis in malignant gliomas.

Authors:  Masahiro Mizoguchi; Daisuke Kuga; Yanlei Guan; Nobuhiro Hata; Akira Nakamizo; Koji Yoshimoto; Tomio Sasaki
Journal:  Brain Tumor Pathol       Date:  2011-06-01       Impact factor: 3.298

6.  Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Authors:  David Matallanas; David Romano; Fahd Al-Mulla; Eric O'Neill; Waleed Al-Ali; Piero Crespo; Brendan Doyle; Colin Nixon; Owen Sansom; Matthias Drosten; Mariano Barbacid; Walter Kolch
Journal:  Mol Cell       Date:  2011-12-23       Impact factor: 17.970

Review 7.  Epigenetics of colon cancer.

Authors:  Sharad Khare; Mukesh Verma
Journal:  Methods Mol Biol       Date:  2012

8.  Human LATS1 is a mitotic exit network kinase.

Authors:  John Bothos; Robyn L Tuttle; Michelle Ottey; Francis C Luca; Thanos D Halazonetis
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

9.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

10.  Decreased expression of LATS1 is correlated with the progression and prognosis of glioma.

Authors:  Tianhai Ji; Dan Liu; Wei Shao; Wensheng Yang; Haiqiao Wu; Xiuwu Bian
Journal:  J Exp Clin Cancer Res       Date:  2012-08-21
View more
  28 in total

1.  Contribution of LATS1 and LATS2 promoter methylation in OSCC development.

Authors:  Mohammad Ayoub Rigi Ladiz; Maryam Najafi; Dor Mohammad Kordi-Tamandani
Journal:  J Cell Commun Signal       Date:  2016-10-19       Impact factor: 5.782

2.  New genetic variants of LATS1 detected in urinary bladder and colon cancer.

Authors:  Mona K Saadeldin; Heba Shawer; Ahmed Mostafa; Neemat M Kassem; Asma Amleh; Rania Siam
Journal:  Front Genet       Date:  2015-01-13       Impact factor: 4.599

Review 3.  Disease implications of the Hippo/YAP pathway.

Authors:  Steven W Plouffe; Audrey W Hong; Kun-Liang Guan
Journal:  Trends Mol Med       Date:  2015-02-18       Impact factor: 11.951

Review 4.  Molecular Pathogenesis of Pancreatic Cancer.

Authors:  T J Grant; K Hua; A Singh
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-15       Impact factor: 3.622

5.  Characterization of Hippo Pathway Components by Gene Inactivation.

Authors:  Steven W Plouffe; Zhipeng Meng; Kimberly C Lin; Brian Lin; Audrey W Hong; Justin V Chun; Kun-Liang Guan
Journal:  Mol Cell       Date:  2016-12-01       Impact factor: 17.970

Review 6.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

7.  Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Authors:  Pinelopi Nterma; Eleni Panopoulou; Eleni Papadaki-Petrou; Martha Assimakopoulou
Journal:  Pathol Oncol Res       Date:  2019-01-02       Impact factor: 3.201

8.  Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.

Authors:  Showkat A Malik; Mosin S Khan; Majeed Dar; Mahboob Ul Hussain; Mohammad A Shah; Sheikh M Shafi; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2017-04-22       Impact factor: 3.201

9.  Connexin 32 and 43 promoter methylation in Helicobacter pylori-associated gastric tumorigenesis.

Authors:  Yu Wang; Li-Hua Huang; Can-Xia Xu; Jing Xiao; Li Zhou; Dan Cao; Xiao-Min Liu; Yong Qi
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 10.  Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.

Authors:  Wei Kang; Alfred S L Cheng; Jun Yu; Ka Fai To
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.